{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    41,
    42,
    43,
    65
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "first dose of study drug",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_llm_1",
        "definition": "The start of the screening/observation period, with Day 1 implicitly following the Day -42 to Day -1 window",
        "anchorType": "Day1",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 80,
        "sourceText": "Screening/observation period (Day -42 to Day -1)",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "baseline visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "Procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_daily_25",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "OD"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "bid"
      },
      {
        "id": "rep_interval_2",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_interval_4",
        "type": "Interval",
        "sourceText": "PK samples at "
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P42D",
        "endOffset": "-P1D",
        "sourceText": "Day -42 to Day -1"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "startOffset": "-P42D",
        "endOffset": "-P1D",
        "sourceText": "Days -42 through Day -1"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "endOffset": "P175D",
        "sourceText": "Day 0 through Day 175"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "startOffset": "P1D",
        "endOffset": "P25D",
        "sourceText": "Weeks 1-25"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "startOffset": "P5D",
        "endOffset": "P26D",
        "sourceText": "Week 5 through Week 26"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "sourceText": "treatment \nperiod"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "dosing window"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "Treatment period"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "observation period"
      },
      {
        "id": "rep_window_15",
        "type": "Continuous",
        "sourceText": "Observation Period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "1 hour post"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "1 hour after"
      },
      {
        "id": "rep_llm_1",
        "type": "Interval",
        "startOffset": "P0D",
        "endOffset": "P1Y",
        "interval": "P3M",
        "minObservations": 4,
        "exitCondition": "Completion of 1st year of treatment in Part B",
        "sourceText": "Samples will be collected at 3-month intervals during the 1st year of treatment in Part B"
      },
      {
        "id": "rep_llm_2",
        "type": "Interval",
        "startOffset": "P1Y",
        "endOffset": "P2Y",
        "interval": "P6M",
        "minObservations": 2,
        "exitCondition": "Remainder of the time on study",
        "sourceText": "then at 6-month intervals for the remainder of the time on study."
      },
      {
        "id": "rep_llm_3",
        "type": "Interval",
        "startOffset": "PT0H",
        "endOffset": "PT1H",
        "interval": "PT1H",
        "minObservations": 2,
        "exitCondition": "null",
        "sourceText": "Collection of PK samples at predose and 1 hour (±15 minutes) postdose was added."
      },
      {
        "id": "rep_llm_4",
        "type": "Continuous",
        "startOffset": "PT0H",
        "endOffset": "PT24H",
        "interval": "PT24H",
        "minObservations": 1,
        "exitCondition": "null",
        "sourceText": "safety assessments include AEs with onset within 24 hours of infusion was added."
      },
      {
        "id": "rep_llm_5",
        "type": "Cycle",
        "startOffset": "P0D",
        "endOffset": "P2Y",
        "interval": "P2Y",
        "minObservations": 1,
        "exitCondition": "24 months following LPO for Part A",
        "sourceText": "The Part B open-label extension study will run for 2 years instead of 1 year following last patient out (LPO) under Part A."
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "epoch_1",
          "epoch_2",
          "epoch_3",
          "epoch_4",
          "epoch_5"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "End of Study (24 months post-LPO Part A)",
          "Screening",
          "Baseline",
          "End of Study",
          "Part A Completion",
          "Part B Year 2 (6-month intervals)",
          "Part B Year 1 (3-month intervals)"
        ],
        "sourceText": "[{'condition': 'Subject at preselected site/country qualifies for home infusion', 'path': ['HOME_INFUSION_ADMINISTRATION', 'HOME_INFUSION_SATISFACTION_ASSESSMENT']}, {'condition': 'ADA testing required', 'path': ['PREDOSE_PD_BACKUP_SAMPLE_TESTING']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 7; RECURRING signals: 2"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Ae",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 4"
      },
      {
        "activityId": "Concomitant Medications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Laboratory Test",
        "executionType": "Single",
        "rationale": "SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Window",
        "rationale": "WINDOW signals: 2"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Window",
        "rationale": "WINDOW signals: 4"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Biopsy",
        "executionType": "Single",
        "rationale": "SINGLE signals: 7"
      },
      {
        "activityId": "Questionnaire",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "ADA sample collection (Part B)",
        "executionType": "Single",
        "rationale": "Samples are collected during the 1st year and then every 6 months, indicating a scheduled repeat at specific intervals."
      },
      {
        "activityId": "Satisfaction with home infusion",
        "executionType": "Single",
        "rationale": "Assessed at two specific scheduled points: after the first home infusion and after the fourth home infusion."
      },
      {
        "activityId": "SLE panel (Part B)",
        "executionType": "Single",
        "rationale": "The protocol introduces additional time points for this panel throughout the Part B extension."
      },
      {
        "activityId": "Immunogenicity assessment (Part A)",
        "executionType": "Single",
        "rationale": "Added as a secondary exploratory objective for Part A to evaluate the drug's immunogenicity profile."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "a. The 6-week Screening/Observation Period may be extended by 1 week for patients requiring a blood transfusion prior to study drug administration.",
        "footnoteId": "fn_1",
        "sourceText": "a. The 6-week Screening/Observation Period may be extended by 1 week for patients requiring a blood "
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "b. Patients should return to the site 9 weeks after last dose for ET procedures, EOS assessment, or Safety Follow-up procedures upon completion of dosing in the study. If patient experiences a hematological breakthrough event, a PK, PD, and ADA sample should be collected at the time of the event.",
        "footnoteId": "fn_2",
        "sourceText": "b. Patients should return to the site 9 weeks after last dose for ET procedures, EOS assessment, or "
      },
      {
        "id": "fn_cond_3",
        "conditionType": "timing_before",
        "text": "c. Applicable to patients who do not have documented vaccination against encapsulated bacterial pathogens within 5 years of enrollment. Refer to immunization recommendations per Section 6.1.1.1 for patients requiring vaccination. A blood sample for vaccine titers will be collected on Day 0 prior to study drug infusion to be used to determine serum relevant antibody titers should the patient be diagnosed with an infection associated with an encapsulated organism during the course of the study. A second sample will be collected during the study period if a patient presents with symptoms concerning for an infection with Streptococcus pneumoniae, Neisseria meningitidis or Haemophilus influenzae and analyzed if the infection is confirmed with one of the aforementioned organisms.",
        "footnoteId": "fn_3",
        "sourceText": "c. Applicable to patients who do not have documented vaccination against encapsulated bacterial path"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "d. Prior bone marrow biopsy report review, prior tissue assessment, or new bone marrow biopsy (as applicable). Sites will submit de-identified biopsy reports to independent central reader for eligibility adjudication. If biopsy is deemed unsuitable or insufficient to determine eligibility, either prior tissue may be submitted for additional hematopathology assessment or a new bone marrow biopsy will be performed during the screening period.",
        "footnoteId": "fn_4",
        "sourceText": "d. Prior bone marrow biopsy report review, prior tissue assessment, or new bone marrow biopsy (as ap"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "timing_at",
        "text": "e. Females of child-bearing potential only. Serum pregnancy test to be performed at Screening. Serum or urine pregnancy test to be performed on Days 0, 21, 49, 77, 105, 133, and 161, and at Week 26/EOT or at the ET Visit. Repeat serum or urine pregnancy test every 4 weeks (±2 days) during Part B.",
        "footnoteId": "fn_5",
        "sourceText": "e. Females of child-bearing potential only. Serum pregnancy test to be performed at Screening. Serum"
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f. Height measured at Screening only. Body weight measured every 3 months during Part B.",
        "footnoteId": "fn_6",
        "sourceText": "f. Height measured at Screening only. Body weight measured every 3 months during Part B."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_after",
        "text": "g. Vital signs measurements (supine BP, PR, RR, and oral temperature) are to be obtained at Screening and at each subsequent visit, with measurements performed predose and 1 hour (±5 minutes) after completion of administration of each dose of study drug.",
        "footnoteId": "fn_7",
        "timingConstraint": "PT1H",
        "sourceText": "g. Vital signs measurements (supine BP, PR, RR, and oral temperature) are to be obtained at Screenin"
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "h. For a complete list of analytes, see protocol (Section 10.1, Appendix A).",
        "footnoteId": "fn_8",
        "sourceText": "h. For a complete list of analytes, see protocol (Section 10.1, Appendix A)."
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_before",
        "text": "i. BIVV009 doses of 6.5 grams (if <75 kg) or 7.5 grams (if ≥75 kg) based on patient's baseline body weight will be administered via IV infusion over ~60 ±5 minutes on Days 0, 7, and every 14 days thereafter during Part A, and every 2 weeks starting at Week 27 during Part B. Patients with underlying cardiopulmonary disease may receive a 2-hour infusion with Sponsor approval. If a patient misses a scheduled dose (outside of the 2-day window or >17 days since last dose), they must return to site (unscheduled visit) to receive another loading dose 1 week prior to the next scheduled dose. Qualifying patients at participating sites may have study drug dosed at home during certain visits in Part B, according to the rules specified in Section 10.10 Appendix J (US, the Netherlands, Norway, France, Italy, Austria, Germany, Spain, and specific amendments.",
        "footnoteId": "fn_9",
        "timingConstraint": "PT5H",
        "sourceText": "i. BIVV009 doses of 6.5 grams (if <75 kg) or 7.5 grams (if ≥75 kg) based on patient's baseline body "
      },
      {
        "id": "fn_cond_10",
        "conditionType": "timing_after",
        "text": "j. During Part A, PK and PD samples will be collected at predose and 1 hour (±15 minutes) postdose (ie, 1 hour after completion of study drug infusion) from all patients on Days 0, 7, 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, and 175. An additional blood sample for PK and PD analysis will be collected during the EOT visit on Day 182 or at ET if a patient withdraws early. During Part B, PK and PD samples will be collected routinely at 3-month intervals during the 1st year of treatment in Part B, and then at 6-month intervals. PK and PD samples will also be collected if a patient experiences a hematologic breakthrough event at any point during the study.",
        "footnoteId": "fn_10",
        "structuredCondition": "timing.after(completion of study drug infusion) from all patients on days 0, 7, 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, and 175. an additional blood sample for pk and pd analysis will be collected during the eot visit on day 182 or at et if a patient withdraws early. during part b, pk and pd samples will be collected routinely at 3-month intervals during the 1st year of treatment in part b, and then at 6-month intervals. pk and pd samples will also be collected if a patient experiences a hematologic breakthrough event at any point during the study., PT1M)",
        "timingConstraint": "PT1H",
        "sourceText": "j. During Part A, PK and PD samples will be collected at predose and 1 hour (±15 minutes) postdose ("
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_after",
        "text": "k. AEs will be recorded from the time the patient signs the informed consent form until 9 weeks after administration of the last dose of study drug.",
        "footnoteId": "fn_11",
        "sourceText": "k. AEs will be recorded from the time the patient signs the informed consent form until 9 weeks afte"
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "l. To be performed every 3 months.",
        "footnoteId": "fn_12",
        "sourceText": "l. To be performed every 3 months."
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "m. Refer to the Laboratory Manual for details of sample collection during Screening.",
        "footnoteId": "fn_13",
        "sourceText": "m. Refer to the Laboratory Manual for details of sample collection during Screening."
      },
      {
        "id": "fn_cond_14",
        "conditionType": "timing_at",
        "text": "n. Samples will be collected for a subset of the disease-related biomarkers at Day 91 only. Refer to the Laboratory Manual for details.",
        "footnoteId": "fn_14",
        "sourceText": "n. Samples will be collected for a subset of the disease-related biomarkers at Day 91 only. Refer to"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "o. During Part B, a 12-lead ECG will be conducting pre- and postdose at 3 months (Day 273).",
        "footnoteId": "fn_15",
        "sourceText": "o. During Part B, a 12-lead ECG will be conducting pre- and postdose at 3 months (Day 273)."
      },
      {
        "id": "fn_cond_16",
        "conditionType": "general",
        "text": "p. During Part B, the healthcare resource utilization data will be recorded every 4 weeks.",
        "footnoteId": "fn_16",
        "sourceText": "p. During Part B, the healthcare resource utilization data will be recorded every 4 weeks."
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_after",
        "text": "q. To be performed in the following order: FACIT-Fatigue first, PGIS second, PGIC third, SF-12 fourth, and EQ-5D-5L fifth.",
        "footnoteId": "fn_17",
        "sourceText": "q. To be performed in the following order: FACIT-Fatigue first, PGIS second, PGIC third, SF-12 fourt"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "timing_after",
        "text": "r. During Part B, ADA samples will be collected at predose at 3-month intervals during the 1st year of treatment in Part B and then at 6-month intervals and at safety follow up visit 9 weeks after last dose. Samples will also be collected if a patient experiences a hematologic breakthrough event or withdraws from the study early.",
        "footnoteId": "fn_18",
        "sourceText": "r. During Part B, ADA samples will be collected at predose at 3-month intervals during the 1st year "
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "s. SLE panel will be performed every 6 months in Part-B of the study.",
        "footnoteId": "fn_19",
        "sourceText": "s. SLE panel will be performed every 6 months in Part-B of the study."
      },
      {
        "id": "fn_cond_20",
        "conditionType": "timing_after",
        "text": "t. In Part B, hematology and clinical chemistry panels to be performed every 2 weeks after Week 25 and up to Week 79. For the remainder of Part B after Week 79, hematology and clinical chemistry panels to be performed every 4 weeks.",
        "footnoteId": "fn_20",
        "sourceText": "t. In Part B, hematology and clinical chemistry panels to be performed every 2 weeks after Week 25 a"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "sequence",
        "text": "u. To be performed at 3-month intervals during the 1st year of treatment in Part B, and then at 6-month intervals.",
        "footnoteId": "fn_21",
        "sourceText": "u. To be performed at 3-month intervals during the 1st year of treatment in Part B, and then at 6-mo"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Efficacy Response (Part A)",
        "endpointType": "Primary",
        "inputs": [
          "Hb",
          "transfusion_history",
          "baseline_Hb"
        ],
        "timeWindow": {
          "reference": "Baseline to Week 26",
          "duration": "P26W"
        },
        "algorithm": "(Hb_increase >= 2 g/dL OR Hb >= 12 g/dL) AND (no_transfusions_from_week_5_to_26) AND (no_prohibited_CAD_treatments)",
        "successCriteria": "Hb increase ≥ 2 g/dL from baseline or Hb ≥ 12 g/dL at treatment assessment with no transfusions from Week 5 through Week 26",
        "sourceText": "The primary efficacy endpoint is the proportion of patients who respond to BIVV009. A responder is defined as a patient who meets the following criteria: Hb increase ≥ 2 g/dL from baseline or Hb ≥ 12 "
      },
      {
        "id": "ep_2",
        "name": "Secondary: Immunogenicity of BIVV009",
        "endpointType": "Secondary",
        "inputs": [
          "ADA_status",
          "ADA_titer"
        ],
        "timeWindow": {
          "reference": "Part A and Part B",
          "duration": "P2Y"
        },
        "algorithm": "Count of subjects with positive Anti-Drug Antibodies (ADA) / Total subjects",
        "successCriteria": "Characterization of immunogenicity profile",
        "sourceText": "Secondary Exploratory Objective for Part A was added: To evaluate the immunogenicity of BIVV009."
      },
      {
        "id": "ep_3",
        "name": "Exploratory: Home Infusion Satisfaction (Part B)",
        "endpointType": "Exploratory",
        "inputs": [
          "satisfaction_score"
        ],
        "timeWindow": {
          "reference": "First and fourth home infusion",
          "duration": "Variable"
        },
        "algorithm": "Score at 4th infusion - Score at 1st infusion",
        "successCriteria": "Assessment of patient satisfaction with convenience of home infusion",
        "sourceText": "Part B Satisfaction with home infusion after first home infusion and after four home infusion will be assessed in patients with home infusion was added."
      },
      {
        "id": "ep_4",
        "name": "Safety: Home Infusion Adverse Events",
        "endpointType": "Secondary",
        "inputs": [
          "AE_onset_time",
          "infusion_time"
        ],
        "timeWindow": {
          "reference": "home infusion",
          "duration": "PT24H"
        },
        "algorithm": "AE_onset_time - infusion_time <= 24 hours",
        "successCriteria": "Identification of treatment-emergent adverse events within 24 hours of home administration",
        "sourceText": "For patients with home infusions, safety assessments include AEs with onset within 24 hours of infusion was added."
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Baseline Body Weight",
        "variableType": "Baseline",
        "sourceVariables": [
          "Body Weight"
        ],
        "derivationRule": "Last non-missing weight measurement prior to the first dose of BIVV009",
        "baselineDefinition": "Prior to treatment start",
        "baselineVisit": "Day 1",
        "analysisWindow": "Pre-dose",
        "imputationRule": "None specified",
        "unit": "kg"
      },
      {
        "id": "dv_2",
        "name": "Dose Group Assignment",
        "variableType": "Categorical",
        "sourceVariables": [
          "Body Weight"
        ],
        "derivationRule": "If weight < 75 kg then 6.5 g; If weight >= 75 kg then 7.5 g (implied by weight-based fixed dosing logic)",
        "baselineDefinition": "Weight at treatment start",
        "baselineVisit": "Day 1",
        "analysisWindow": "Baseline",
        "imputationRule": "None specified",
        "unit": "g"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening/observation period",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening/observation period",
        "Baseline",
        "Part A",
        "Part B Extension phase",
        "ET/EOS/Safety follow-up",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening/observation period",
          "toState": "Baseline",
          "trigger": "Progress to Baseline"
        },
        {
          "fromState": "Baseline",
          "toState": "Part A",
          "trigger": "Progress to Part A"
        },
        {
          "fromState": "Part A",
          "toState": "Part B Extension phase",
          "trigger": "Progress to Part B Extension phase"
        },
        {
          "fromState": "Part B Extension phase",
          "toState": "ET/EOS/Safety follow-up",
          "trigger": "Progress to ET/EOS/Safety follow-up"
        },
        {
          "fromState": "Screening/observation period",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening/observation period": "epoch_1",
        "Baseline": "epoch_2",
        "Part A": "epoch_3",
        "Part B Extension phase": "epoch_4",
        "ET/EOS/Safety follow-up": "epoch_5",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "Trial Protocol",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 6.0,
            "unit": "g"
          },
          {
            "amount": 4.0,
            "unit": "g"
          },
          {
            "amount": 5.0,
            "unit": "g"
          }
        ],
        "sourceText": "Protocol 06 Page 2 of 99 Bioverativ USA Inc. Confidential PROTOCOL AMENDMENT SUMMARY OF CHANGES DOCUMENT HISTORY Document Country/Countries impacted by amendment Date Amended Clinical Trial Protocol 0"
      },
      {
        "id": "dosing_2",
        "treatmentName": "Protocol Version",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "g"
          },
          {
            "amount": 3.0,
            "unit": "g"
          },
          {
            "amount": 4.0,
            "unit": "g"
          },
          {
            "amount": 6.0,
            "unit": "g"
          }
        ],
        "sourceText": "ial PROTOCOL AMENDMENT SUMMARY OF CHANGES DOCUMENT HISTORY Document Country/Countries impacted by amendment Date Amended Clinical Trial Protocol 06 Global 19 December 2019 Clinical Study Protocol Vers"
      },
      {
        "id": "dosing_3",
        "treatmentName": "BIVV009 is",
        "frequency": "QW",
        "route": "IV",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 180.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "26 weeks",
        "sourceText": "ffects from exaggerated pharmacology (ie, autoimmune diseases, bacterial infections) were observed in those studies. As a result, the no observed adverse effect (dose) level (NOAEL) established for BI"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "BIVV009",
        "frequency": "Q2W",
        "route": "IV",
        "startDay": 1,
        "durationDescription": "Part A (duration not specified in snippet) followed by Part B (2 years)",
        "doseModifications": [
          "Home infusion facilities provided for specific countries in Part B"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_3",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Section 6.1.1.1: Screening Assessments (initiating at Day -42)"
      },
      {
        "id": "visit_1",
        "visitName": "Visit 009",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "BIVV009-03 Cardinal Amended Clinical Trial Protocol 06 Page 5 of 99"
      },
      {
        "id": "visit_2",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "epoch": "Follow-up",
        "sourceText": "following completion of LPO in Part A. The change was made to gather more evidence on long-term safety, tolerability"
      },
      {
        "id": "visit_7",
        "visitName": "end of study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "early termination/end of study/safety follow-up was renumbered as 6.1.7. This change was made to evaluate the"
      },
      {
        "id": "visit_11",
        "visitName": "EOT",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "EOT end of treatment EQ-5D-5L"
      },
      {
        "id": "visit_12",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "baseline visit (and first infusion of study drug) must occur at least 7 days following the transfusion. Part A"
      },
      {
        "id": "visit_19",
        "visitName": "Visit 9",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "Follow up visit 9 weeks after last dose. Samples will also be collected if a patient experiences a hematologic breakthrough or withdraws from the study. SAMPLE SIZE:"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Part B Extension Phase (Bi-weekly)",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Part B Extension Phase"
      },
      {
        "id": "visit_10",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "sourceText": "Randomization ............................................................................................................................... 54 6.2.4 Dose preparation and administration ............."
      },
      {
        "id": "visit_4",
        "visitName": "Day 7",
        "targetDay": 7,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 10,
        "epoch": "Part A",
        "sourceText": "points Day 7, 35, 77, 133 and 175, may be used to assay ADA was added. This change was made to help characterize"
      },
      {
        "id": "visit_16",
        "visitName": "Week 5",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 5,
        "sourceText": "transfusion from Week 5 through Week 26 (EOT) and did not receive treatment for CAgD beyond what is permitted per protocol. Additionally, the patient’s Hgb level must meet either of the following crit"
      },
      {
        "id": "visit_llm_3",
        "visitName": "Day 35",
        "targetDay": 35,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 3,
        "targetWeek": 5,
        "epoch": "Part A"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Day 77",
        "targetDay": 77,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 11,
        "epoch": "Part A"
      },
      {
        "id": "visit_22",
        "visitName": "Day 91",
        "targetDay": 91,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "(Day 91 only) Xo"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Day 133",
        "targetDay": 133,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 19,
        "epoch": "Part A"
      },
      {
        "id": "visit_18",
        "visitName": "Week 23",
        "targetDay": 155,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 23,
        "sourceText": "Week 23, 25, and 26)  Mean change from baseline in QOL, as assessed by the change in Functional"
      },
      {
        "id": "visit_13",
        "visitName": "Week 25",
        "targetDay": 169,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 17,
        "targetWeek": 25,
        "sourceText": "60 minutes on Day 0, Day 7, and every 14 days thereafter through Week 25 (ie, Days 21, 35, 49, 63, 77, 91, 105, 119, 133, 147, 161, and 175). Patients who miss a dose (ie, outside the dosing window or"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Day 175",
        "targetDay": 175,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 25,
        "epoch": "Part A"
      },
      {
        "id": "visit_5",
        "visitName": "Week 26",
        "targetDay": 176,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 26,
        "sourceText": "(Week 26) ADA: In patients who consented to the use of their blood samples for future research, PD"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 1",
        "targetDay": 182,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 26,
        "epoch": "Part A",
        "sourceText": "visit 1 week prior to the next scheduled dose in order to receive an additional loading dose. Patients will have an End-of-Treatment (EOT) visit in Part A on Day 182 (Week 26). Patients who meet the t"
      },
      {
        "id": "visit_17",
        "visitName": "Week 27",
        "targetDay": 183,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 21,
        "targetWeek": 27,
        "sourceText": "Bi-weekly dosing starting at Week 27 and continuing for 2 years after LPO in Part A"
      },
      {
        "id": "visit_20",
        "visitName": "Week 41",
        "targetDay": 281,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "targetWeek": 41,
        "sourceText": "qualified by the Investigator and no sooner than after Week 41 (Day 287) and without evidence of intolerance of the study drug as determined by the Investigator. No new risks related to home infusions"
      },
      {
        "id": "visit_21",
        "visitName": "Day 287",
        "targetDay": 287,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 23,
        "sourceText": "qualified by the Investigator and no sooner than after Week 41 (Day 287) and without evidence of intolerance of the study drug as determined by the Investigator. No new risks related to home infusions"
      },
      {
        "id": "visit_8",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 24,
        "sourceText": "early termination/end of study/safety follow-up was renumbered as 6.1.7. This change was made to evaluate the"
      },
      {
        "id": "visit_6",
        "visitName": "Week 79",
        "targetDay": 547,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 25,
        "targetWeek": 79,
        "epoch": "Part B Extension Phase",
        "sourceText": "week 79. This change was made to reflect the study assessments frequency in the 2nd year of"
      }
    ]
  }
}